*September 2020*
The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1 CHRYSALIS study that were presented during the 2020 ESMO Virtual Congress.
Amivantamab is a fully human bispecific antibody that targets EGFR and MET. The antibody has immune cell-directing activity, including antibody-dependent cell cytotoxicity, and demonstrated clinical activity in patients with primary and acquired EGFR resistance mutations. Lazertinib is a potent third-generation EGFR TKI that demonstrated activity in patients with activating EGFRmutations, T790M resistance mutations, and central nervous system (CNS) disease. With low rates of EGFR-related toxicity, such as rash and diarrhea, the safety profile of the agent supports its use in combination with other EGFR inhibitors. Read more.
